| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Kaitlyn Arsenault is Chief Financial Officer at SKYE. Kaitlyn Arsenault's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $203K at current prices.
The SKYE filings lean toward selling, a net 43,396 shares.
Kaitlyn Arsenault has 9 Form 4 filings on record from October 2021 to February 2026, all as Chief Financial Officer at Skye Bioscience (SKYE), 2021–2026.
The 14 reported transactions were 8 option or other derivative awards, 4 stock awards and 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $217K.
The only open-market sale was 43,396 shares of SKYE at an average $4.99 on November 18, 2024, about $217K. Twelve months later SKYE was down 71%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2024 | SKYE Skye Bioscience, Inc. | Chief Financial Officer | Sell | 43,396 | $4.99 | $216,652.44 | -20.7% | -31.8% | -70.8% |